Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

What Kuwait Women Knew About GLP-1s

A Kuwait survey found high tirzepatide and semaglutide awareness, but sharp differences in information sources and risk perceptions.

Why we wrote this. High medicine recognition can hide gaps in understanding. This survey separates awareness, information sources and risk perception without treating them as clinical outcomes.

In this article (5 sections)
  1. What the Kuwait survey measured
  2. Users reported different information sources
  3. Risk perceptions differed by use history
  4. What the findings can support
  5. What we don't yet know

An online survey of 445 adult women living in Kuwait found broad awareness of GLP-1 and dual GIP/GLP-1 medicines, but much less consistency in what participants understood and where they obtained information. Awareness was highest for tirzepatide at 88.6%, followed by semaglutide at 73.4%. Social media was the most frequently reported information source overall, named by 56.0% of participants[1].

The study, published online in Clinical Therapeutics on 9 November 2026, does not measure whether either medicine caused weight loss or adverse effects. It examines knowledge, perceptions, information sources and reported experience. That distinction is important because the results describe one survey sample, not the clinical benefits and risks of treatment[1].

What the Kuwait survey measured

Researchers ran the cross-sectional survey from March through June 2026. Cross-sectional means that responses were collected over one period rather than following participants forward to see how their views changed. Eligible participants were women aged 18 or older who lived in Kuwait. The questionnaire covered awareness, knowledge, information sources, attitudes, medication use and factors involved in treatment decisions[1].

Of the 445 respondents, 132, or 29.7%, reported current or previous use of a GLP-1 or dual GIP/GLP-1 medicine. The researchers compared that group with participants who had never used one or were considering future use. They also fitted selected regression models that adjusted for age, body mass index and intention to manage weight[1]. Adjustment can reduce measured differences linked to those recorded factors. It cannot remove every source of bias or turn an observational survey into a randomized experiment.

The abstract says knowledge of mechanisms and adverse effects varied, even though name recognition was high[1]. Recognizing a medicine is therefore not the same as understanding what it does, which harms are established, or whether it fits an individual medical history. The published abstract does not provide every questionnaire item or a single score that would justify calling the sample well informed or poorly informed overall.

Users reported different information sources

Previous or current users were far more likely to name healthcare professionals as an information source than people who had never used the medicines or were only considering them: 57.6% compared with 10.2%. They were less likely to name social media, at 38.6% compared with 63.3%. Both comparisons had p values below 0.001, and the differences remained after adjustment for age, body mass index and weight-management intention[1].

Those figures do not show what happened first. Contact with a clinician may have shaped a participant's views, or people who had already decided to seek treatment may have been more likely to consult a clinician. Both could be true. The study design cannot establish the direction of that relationship, and a reported information source does not show whether its advice was accurate, detailed or decisive.

A 2025 UK cross-sectional survey provides a useful comparison, but not a direct benchmark. Among 1,297 UK adults recruited through online routes, news was reported by 60.1% and social media by 50.3% as main information sources, while 9.0% first learned about GLP-1 medicines from healthcare providers[2]. The Kuwait and UK samples used different recruitment methods, questions and populations, so their percentages should not be ranked as if they came from one survey.

Risk perceptions differed by use history

In the Kuwait survey, 24.2% of previous or current users said they perceived that medication risks outweighed benefits, compared with 59.4% of never-users and those considering use. This difference also remained after the authors' stated adjustments[1]. The result records perception. It does not calculate each participant's clinical risk or prove that one group assessed the evidence more accurately.

The UK survey found a similar association between use history and lower scepticism about safety and efficacy[2]. A 2024 online survey in Jordan, which analyzed 389 responses, also found uneven recognition of named medicines and reported that 12.3% of participants had used medication to lose weight[3]. Across these online samples, knowledge and attitudes varied. The results do not establish a Gulf-wide pattern or allow a clean country comparison.

Use can change perception through personal experience, clinical counselling or both. Selection also matters: people who judge the risks more favorably may be more willing to start treatment. Because the Kuwait study measured use history and perception in the same survey period, it cannot separate those explanations.

What the findings can support

The authors conclude that accessible, evidence-based medication information from healthcare professionals could support informed decisions[1]. The survey supports that as an information need, especially given the gap between high name recognition and variable understanding. It does not test an educational program, compare counselling formats or show that one message would work for every woman in Kuwait.

For a reader, the practical lesson is modest. A social post can alert someone that a medicine exists, but it cannot account for personal contraindications, other medicines or the difference between approved uses and online claims. Questions about expected benefits, adverse effects and suitability belong in a discussion with a qualified healthcare professional who can review the person's medical history.

What we don't yet know

The PubMed record does not report how closely the respondents matched all adult women in Kuwait, the survey completion rate, detailed recruitment channels or responses to every knowledge item. Online recruitment can miss people with limited internet access and can attract people who already have a strong interest in weight management or these medicines. Self-reported use was not described as being checked against prescriptions or medical records.

We also do not know from this study whether professional counselling changed knowledge, whether social-media information was accurate, or how perceptions changed after treatment. The survey included women only, so it cannot describe men in Kuwait. Longer follow-up and intervention studies would be needed to test whether specific education improves understanding or decision quality.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

How many women took part in the Kuwait GLP-1 survey?

The online cross-sectional survey included 445 women aged 18 or older who lived in Kuwait. Of them, 132, or 29.7%, reported previous or current use of a GLP-1 or dual GIP/GLP-1 medicine.

Which medicine had the highest awareness in the survey?

Tirzepatide had the highest reported awareness at 88.6%, followed by semaglutide at 73.4%. High recognition did not mean that every participant understood mechanisms or adverse effects.

Did most participants get GLP-1 information from social media?

Social media was the most frequently reported information source overall at 56.0%. It was reported by 38.6% of previous or current users and 63.3% of never-users or people considering future use.

Does the survey show that GLP-1 medicines are safe for everyone?

No. The survey measured knowledge, information sources, attitudes and reported experience. It did not determine individual clinical suitability or test the safety and efficacy of treatment.

Sources

  1. [1]Kuwait GLP-1/GIP medication survey, PubMed PMID 43003739Tier 1 · primary↩
  2. [2]UK community GLP-1 perspectives survey, PMC12306312Tier 1 · primary↩
  3. [3]Jordan GLP-1 knowledge and attitudes survey, PMC11620468Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.